In short
Clinical trials are studying HEMOPEXIN, HUMAN in people with sickle cell disease during vaso-occlusive crisis. These trials look at safety, tolerability, and how well the treatment may help symptoms improve faster. The main study includes adults and adolescents.
Key points
- Clinical trials of HEMOPEXIN, HUMAN are studying people with sickle cell disease who are having a vaso-occlusive crisis. The main trial is a Phase 4 study in adults and adolescents. Researchers are looking at safety, tolerability, and whether the treatment can shorten the crisis. They are also measuring time to stopping parenteral opioids, which is a sign that pain is improving. The study includes 260 participants and has been completed.
Trial overview
The available study of HEMOPEXIN, HUMAN was an interventional trial, which means researchers gave a study treatment and watched the results. The trial studied people with sickle cell disease vaso-occlusive crisis, a painful episode caused by blocked blood flow.
The study title says it evaluated safety, efficacy, and pharmacokinetics of CSL889 in adults and adolescents with sickle cell disease during vaso-occlusive crisis. In the trial data, CSL889 is identified as HEMOPEXIN, HUMAN.
Who participated
The trial included adults and adolescents with sickle cell disease who were having a vaso-occlusive crisis. This means the study focused on patients during an active painful event, not on people without symptoms.
The enrollment was 260 participants, so this was a fairly large study for this condition.
What was studied
The main goal was to evaluate the safety and tolerability of HEMOPEXIN, HUMAN given by intravenous infusion. Safety means whether unwanted medical problems happen, and tolerability means how manageable the treatment is for patients.
The study also looked at whether HEMOPEXIN, HUMAN could help reduce the time needed for vaso-occlusive crisis to resolve. In simple terms, the researchers wanted to know if the painful episode could end sooner.
The intervention list shows that participants received either HEMOPEXIN, HUMAN or a placebo solution for infusion. A placebo is a look-alike infusion with no active substance, used for comparison.
Main endpoints
The primary outcome included time to resolution of vaso-occlusive crisis, measured as the time until parenteral opioids could be stopped. This is a practical way to track when severe pain is improving enough that strong injected or infused pain medicine is no longer needed.
The trial also measured treatment-emergent adverse events, which are medical problems that start or get worse after treatment begins. Both the number of participants with these events and the percentage of participants affected were recorded.
Another endpoint was the number and percentage of participants with detectable treatment-emergent anti-CSL889 antibodies. Antibodies are proteins made by the immune system, and this measure checks whether the body reacted to the study treatment.
Trial phase and status
This study was a Phase 4 trial. Phase 4 studies are later-stage trials that examine a treatment in a broader patient setting.
The trial status was Completed. That means the planned study activities were finished.
What the study means for patients
For patients with sickle cell disease, this trial was designed to see whether HEMOPEXIN, HUMAN could help during a painful vaso-occlusive crisis while also being monitored for safety. The study focused on a real hospital-style situation where patients often need strong pain treatment.
Because the trial compared HEMOPEXIN, HUMAN with placebo, the results were meant to show whether any changes seen were likely due to the study treatment rather than chance alone. The main patient-centered outcome was how quickly the crisis ended and pain medicine could be stopped.